Current average analyst rating on the shares is buy, with 5 strong buy or buy ratings, 1 hold, and no sell or strong sell ratings.
Wall Street's median 12-month price target for Century Therapeutics, Inc. is $5.00, about 142.7% above its August 11 closing price of $2.06.
Quarterly loss widens on lease termination loss
U.S. cell therapy developer's Q2 net loss widened year over year, missing analyst expectations.
Q2 operating income also missed analyst expectations.
Century said lower Q2 R&D and G&A expenses were primarily due to reduced personnel and facility costs after portfolio prioritization, but the company recorded an $11.1 million loss on lease component termination in the quarter.
Company ended Q2 with $197.2 million in cash and investments.
IPSC•
